Is There a Role for Perioperative Adjuvant Cytotoxic Therapy in the Treatment of Early Breast Cancer?
The use of perioperative adjuvant therapy in the treatment of breast cancer is not new; its history goes back to the mid-1960s when several groups experimented with the use of the then relatively new cytotoxic agents, giving them at about the same time as primary surgery. The conclusions drawn by the various authors show that controversy is not new to this field!
KeywordsToxicity Tamoxifen Peri Cyclophosphamide Alopecia
Unable to display preview. Download preview PDF.
- Anonymous (1984) Review of mortality results in randomised trials in early breast cancer. Lancet II: 1035–1036Google Scholar
- Finney R (1971) Adjuvant chemotherapy in the radical treatment of carcinoma of the breast — a clinical trial. Am J Roentgenol III: 137–141Google Scholar
- Goldhirsch A (1988) Early results of randomised perioperative therapy in operable breast cancer: the Ludwig Breast Cancer Study V, presented at 3rd international conference on adjuvant therapy of primary breast cancer.Google Scholar
- Mrazek RG, McDonald GO (1970) Surgery and adjuvant chemotherapy in treatment for breast carcinoma. Oncology — Proceedings of the tenth international cancer congress, Houston, Texas, p. 501Google Scholar
- Nissen-Meyer R (1979) Adjuvant cytostatic and endocrine therapy: increased cure rate or delayed manifest disease. In: Commentaries on research in breast disease 1. Liss, New York.Google Scholar
- Nissen-Meyer R, Kjellgren K, Mansson B (1971) Preliminary report from the Scandinavian adjuvant chemotherapy study group. Cancer Chemotherapy Reports 55: 561–566Google Scholar